• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >Overview of the latest treatments for castration-resistant prostate cancer
【24h】

Overview of the latest treatments for castration-resistant prostate cancer

机译：去势抵抗性前列腺癌的最新治疗方法概述

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Over the past few years, we have developed an increased understanding of the molecular mechanisms that underlie prostate cancer progression and castration resistance and expanded our repertoire of therapeutic options for castration-resistant prostate cancer (CRPC). Four new agents (cabazitaxel, abiraterone acetate, enzalutamide, and radium-233) have been shown to prolong overall survival in patients with CRPC in the postchemotherapy setting. Targeting the androgen receptor pathway continues to have an important role in the treatment of CRPC, with abiraterone acetate and enzalutamide being the most exciting developments. Cabazitaxel is now considered the standard-of-care second-line chemotherapy for men with metastatic CRPC (mCRPC). Bone-targeted therapy is an active area of research, with denosumab being the first bone-targeted agent able to significantly delay the appearance of bone metastases in patients with CRPC and radium-223 being the first radiopharmaceutical agent to improve survival in patients with mCRPC.
机译：在过去的几年中，我们对构成前列腺癌进展和去势抵抗的分子机制有了更深入的了解，并扩大了我们对去势抵抗性前列腺癌（CRPC）的治疗选择的范围。四种新药（卡巴他赛，醋酸阿比特龙，恩杂鲁胺和镭233）已显示出可在化疗后延长CRPC患者的总生存期。靶向雄激素受体途径在CRPC的治疗中继续发挥重要作用，其中乙酸阿比特龙酯和enzalutamide是最令人兴奋的发展。现在，卡巴他赛被认为是转移性CRPC（mCRPC）男性的护理标准二线化疗。骨靶向治疗是研究的活跃领域，denosumab是第一种能够显着延迟CRPC患者骨转移出现的骨靶向药物，而radium-223是提高mCRPC患者生存率的第一种放射性药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号